IP Library Granted Patent US 9,150,894
Granted Patent B2
US 9,150,894 · App. 12/708,539 · Granted Oct 6, 2015

Process for purifying lipopeptides

Inventors: Martin Mansson (Oslo, NO); Eli Karin Dale (Oslo, NO); Sissel Hauge (Oslo, NO); Carsten Overballe-Petersen (Hvidovre, DK); Kjersti Aastorp Hirth (Oslo, NO); Dennis Brian Hansen (Rodovre, DK)
Assignee: XELLIA PHARMACEUTICALS APS
C12P17/188C07K1/36C12P21/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,150,894
App. No.
12/708,539
Granted
Oct 6, 2015
Kind
B2
Abstract

The present invention relates to a process for purifying lipopeptides. More particular, the invention provides an improved method for purifying daptomycin.

Claims (30)

1. A process for purifying daptomycin comprising

a) loading a solution comprising partly purified daptomycin onto an anion exchange chromatography column and eluting a first eluate with a first elution buffer; wherein the partially purified daptomycin is optionally clarified from a fermentation broth comprising daptomycin using one or several clarification steps;

b) loading the first eluate of step a) onto a first reverse phase chromatography column and eluting a second eluate with a second elution buffer having a pH of 6.5-8.5;

c) loading the second eluate of step b) onto a second reverse phase chromatography column and eluting a third eluate with a third elution buffer having a pH of 2.5-3.5; and

d) optionally filtering and lyophilizing the third eluate;

wherein the first elution buffer in a) is a monovalent salt solution, the second elution buffer in b) consists of water and an alcohol, and the third elution buffer in c) consists of water, an alcohol and an acid.

2. A process according to of claim 1 , wherein a purified daptomycin product of the reverse phase chromatography step c) is further purified by one or more filtration steps to produce a filtered product.

3. A process according to claim 2 , wherein the filtered product is subjected to a lyophilisation step to produce a lyophilized product.

4. A process according to claim 1 , wherein the salt of the monovalent salt solution of the first elution buffer in a) is NaCl.

5. A process according to claim 4 , wherein the first elution buffer is 0.1-1.5 M NaCl.

6. A process according to claim 1 , wherein the second elution buffer in b) is aqueous ethanol.

7. A process according to claim 6 , wherein the second elution buffer is 5-80% ethanol.

8. A process according to claim 1 , wherein the anion exchange chromatography step is performed using a highly cross-linked agarose resin with dextran surface extender.

9. A process according to claim 1 , wherein the first reverse phase chromatography step is performed using a styrene based resin column.

10. A process according to claim 1 , wherein the first reverse phase chromatography column is eluted at pH 7.5-8.0.

11. A process according to claim 1 , wherein the second reverse phase chromatography column is eluted at pH 3.0-3.1.

12. A process for purifying daptomycin, consisting of

a) subjecting a fermentation broth comprising daptomycin to one or several clarification steps to produce a solution;

b) loading the solution of step a) onto an anion exchange chromatography column and eluting a first eluate with a first elution buffer;

c) loading the first eluate of step b) onto a first reverse phase chromatography column and eluting a second eluate with a second elution buffer having a pH of 6.5-8.5;

d) loading the second eluate of step c) onto a second reverse phase chromatography column and eluting a third eluate with a third elution buffer having a pH of 2.5-3.5;

e) subjecting the third eluate of step d) to one or several filtration steps to produce a filtrate; and

f) subjecting the filtrate to lyophilisation; producing a purified powder of daptomycin;

wherein the first elution buffer in b) is a monovalent salt solution,

and wherein the second elution buffer consists of an alcohol and water, and the third elution buffer consists of water, an alcohol and an acid.

13. A process according to claim 12 , wherein the clarification steps in a) are selected from the group consisting of reverse osmosis, centrifugation, filtration, ultrafiltration, nanofiltration, anion exchange chromatography, and combinations thereof.

14. A process according to claim 12 , wherein the salt of the monovalent salt solution of the first elution buffer in b) is NaCl.

15. A process according to claim 14 , wherein the first elution buffer is 0.1-1.5 M NaCl.

16. A process according to claim 12 , wherein the second elution buffer in c) is aqueous ethanol.

17. A process according to claim 16 , wherein the second elution buffer is 5-80% ethanol.

Assignments (2)
CHANGE OF NAME Recorded Nov 3, 2010
From: AXELLIA PHARMACEUTICALS APS
To: XELLIA PHARMACEUTICALS APS
Reel/Frame 025237/0789 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2010
From: MANSSON, MARTIN; DALE, ELI KARIN; HAUGE, SISSEL; HIRTH, KJERSTI AASTORP; PETERSEN, CARSTEN OVERBALLE; HANSEN, DENNIS BRIAN
To: AXELLIA PHARMACEUTICALS APS
Reel/Frame 024398/0479 →
Continuity (2)
Provisional Application 61153660 · Feb 19, 2009
Related Publication 20100228006A1 · Sep 9, 2010